Your CRO Partner For
in vivo Pharmacology

Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.

In Vivo Efficacy

Indications Discovery

Specialized Animal Models

Drug Repositioning

Your CRO Partner For
In Vivo Pharmacology

Melior Discovery is a dedicated in vivo pharmacology CRO that strives to provide the highest quality service. We offer access to individual animal models and our theraTRACE® platform as contract research or on collaborative research basis. Our commitment to in vivo services since 2005 has made us a CRO of choice for hundreds of companies.

Melior Drug Discovery Philosophy

Watch the video

In Vivo Efficacy

Indications Discovery

Specialized Animal Models

Drug Repositioning

Andrew Reaume, PhD, CEO Melior Discovery



Trusted by the Top Leaders in Pharmacology

Melior Discovery's founding mission is drug repositioning - that is finding new uses for existing drugs.

State-of-the-art Preclinical Pharmacology Support

Melior provided state-of-the-art preclinical pharmacology support for a period of nearly a year, where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.

– Richard DiMarchi, PhD

Cox Professor of Chemistry & Gill Chair in Biomolecular Sciences
Indiana University, Department of Chemistry

State-of-the-art Preclinical Pharmacology Support

Melior provided state-of-the-art preclinical pharmacology support for a period of nearly a year, where a series of in vivo studies were completed on a weekly basis. The staff was extremely user-friendly and the operational processes were excellent. I can recommend Melior without reservation.

Richard DiMarchi, PhD

Cox Professor of Chemistry & Gil Chair in Biomolecular Sciences Indiana University, Department of Chemistry

Phenotypic screening uncovers otherwise
unpredicted new uses for a drug

Our in vivo pharmacology contract research capabilities

Phenotypic screening platform (theraTRACE® ) suited for drug repositioning

Learn about our in vivo pharmacology

contract research capabilities in most therapeutic areas.

Melior has pioneered a phenotypic

screening platform (theraTRACE® ) suited for drug repositioning or for identifying novel indications from development-stage candidates.

Serving our community since 2005

8000

Thousands of studies

800

Hundreds of compounds evaluated

80

Dozens of animal models of human disease

Our Drug Discovery Philosophy

Increasingly, phenotypic screening is being recognized as the best strategy to uncover otherwise unpredicted new uses of therapeutics.

Recent Studies using Phenotypic Screening

A Functionally Robust Phenotypic Screen that Identifies Drug Resistance-associated Genes Using 3D Cell Culture.
Lee SY, Bissell MJ. Bio Protoc. 2018 Nov 20;8(22). pii: e3083. doi: 10.21769/BioProtoc.3083.

Drug resistance is a major obstacle in cancer treatment: A case in point is the failure of cancer patients to respond to tyrosine kinase inhibitors (TKI) of EGFR, a receptor that is….

Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT-β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2.
Poirier M, Awale M, Roelli MA, Giuffredi GT, Ruddigkeit L, Evensen L, Stooss A, Calarco S, Lorens JB, Charles RP, Reymond JL. ChemMedChem. 2019 Jan 22;14(2):224-236. doi: 10.1002/cmdc.201800554. Epub 2018 Dec 6

By screening a focused library of kinase inhibitor….